| Entry |
|
|---|
| Name |
Desloratadine (JAN/USAN/INN);
Clarinex (TN)
|
|---|
| Product |
|
|---|
| Generic |
DESLORATADINE (AvKARE), DESLORATADINE (AvKARE), DESLORATADINE (AvPAK), DESLORATADINE (Belcher Pharmaceuticals), DESLORATADINE (Bryant Ranch Prepack), DESLORATADINE (Dr. Reddy's Laboratories Limited), DESLORATADINE (Lupin Pharmaceuticals), DESLORATADINE (Mylan Pharmaceuticals), DESLORATADINE (Paddock Laboratories), DESLORATADINE (Sandoz), DESLORATADINE (Sun Pharmaceutical Industries Limited), DESLORATADINE (Taro Pharmaceuticals U.S.A.), DESLORATADINE (Virtus Pharmaceuticals), DESLORATADINE (Virtus Pharmaceuticals) |
|---|
| Formula |
C19H19ClN2
|
|---|
| Exact mass |
310.1237
|
|---|
| Mol weight |
310.8206
|
|---|
| Structure |
     |
|---|
| Simcomp |
 |
|---|
| Class |
Anti-allergic agent
DG01557 Histamine receptor antagonist
DG01482 Histamine receptor H1 antagonist
|
|---|
| Remark |
Therapeutic category: ATC code: |
|---|
| Activity |
Antiallergic, Antipruritic, H1 receptor antagonist |
|---|
| Disease |
|
|---|
| Comment |
Treatment of seasonal allergic rhinitis
|
|---|
| Target |
|
|---|
| Pathway |
| Calcium signaling pathway | | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
R RESPIRATORY SYSTEM
R06 ANTIHISTAMINES FOR SYSTEMIC USE
R06A ANTIHISTAMINES FOR SYSTEMIC USE
R06AX Other antihistamines for systemic use
R06AX27 Desloratadine
D03693 Desloratadine (JAN/USAN/INN)
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Antihistamines
Desloratadine
D03693 Desloratadine (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
44 Allergic agents
449 Miscellaneous
4490 Miscellaneous
D03693 Desloratadine (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Histamine
H1-receptor
Desloratadine
D03693 Desloratadine (JAN/USAN/INN)
New drug approvals in the USA [br08319.html]
New Molecular Entity and New Therapeutic Biological Product Approvals
D03693
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03693
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03693
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03693
 |
|---|
| Other DBs |
CAS: 100643-71-8 PubChem: ChEBI: ChEMBL: DrugBank: LigandBox: |
|---|
| KCF data |
ATOM 22
1 C1x C 15.9600 -18.2700
2 C8y C 15.1200 -17.1500
3 C8y C 15.4000 -15.7500
4 C2y C 16.7300 -15.1900
5 C1x C 17.3600 -18.2700
6 C8y C 17.9200 -15.8200
7 C8y C 18.2700 -17.2200
8 C8x C 14.4200 -14.8400
9 C8x C 13.0900 -15.1900
10 C8y C 12.7400 -16.5900
11 C8x C 13.7200 -17.5000
12 C8x C 19.6000 -17.6400
13 C8x C 20.6500 -16.7300
14 C8x C 20.3700 -15.3300
15 N5x N 18.9700 -14.9100
16 C2y C 16.7300 -13.7900
17 X Cl 11.3979 -16.9886
18 C1x C 17.9424 -13.0900
19 C1x C 17.9424 -11.6900
20 N1x N 16.7300 -10.9900
21 C1x C 15.5176 -11.6900
22 C1x C 15.5176 -13.0900
BOND 25
1 3 4 1
2 1 5 1
3 4 6 1
4 2 3 1
5 5 7 1
6 1 2 1
7 6 7 1
8 3 8 2
9 8 9 1
10 9 10 2
11 10 11 1
12 2 11 2
13 7 12 2
14 12 13 1
15 13 14 2
16 14 15 1
17 6 15 2
18 4 16 2
19 10 17 1
20 16 18 1
21 18 19 1
22 19 20 1
23 20 21 1
24 21 22 1
25 16 22 1
|
|---|
